The Use of Bacitracin for Identifying Group A Haemolytic Streptococci
Open Access
- 1 August 1953
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 6 (3) , 224-226
- https://doi.org/10.1136/jcp.6.3.224
Abstract
Only 1.7% of bacitracin-sensitive strains proved not to be Group A, and only 2.5% of resistant strains were Group A. Sterile, dried filter paper disks previously soaked in bacitracin in glycine-phosphate buffer or a commercial sample of bacitracin (Pfizer), 5 U. per ml., were placed on subcultured colonies in blood agar plate and incubated for the definitive testing.Keywords
This publication has 7 references indexed in Scilit:
- SOME OBSERVATIONS ON THE BIOLOGICAL PROPERTIES OF BACITRACINS A, B, AND CBritish Journal of Pharmacology and Chemotherapy, 1951
- Ayfivin and bacitracin: resolution of crude products into similar series of peptidesBiochemical Journal, 1950
- AYFIVIN - PRODUCTION IN CHEMICALLY DEFINED MEDIA AND COMPARISON WITH LICHENIFORMIN1949
- PREPARATION OF STREPTOCOCCAL EXTRACTS FOR LANCEFIELD GROUPINGThe Lancet, 1948
- Antibiotic Material from Bacillus licheniformis (Weigmann, emend. Gibson) Active Against Species of MycobacteriaNature, 1946
- Bacitracin: A New Antibiotic Produced by a Member of the B. subtilis GroupScience, 1945
- CULTIVATION OF β -HAEMOLYTIC STREPTOCOCCI ON MALTOSE-BLOOD-AGAR: A PRESUMPTIVE TEST FOR GROUP AThe Medical Journal of Australia, 1941